Johnson & Johnson Business Combination, Consideration Transferred
Johnson & Johnson (JNJ) reported Business Combination, Consideration Transferred of $7.30 billion for the 12-month period ending 2022-01-02, per its 10-K filed 2023-02-16.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2023-02-16
- Johnson & Johnson business combination, consideration transferred for fiscal 2022 was $7.30B, a 0.00% change from fiscal 2021.
- Johnson & Johnson business combination, consideration transferred for fiscal 2021 was $7.30B.
| Period end | Business Combination, Consideration Transferred 12 month |
|---|---|
| 2022-01-02 | $7.30B 10-K · filed 2023-02-16 |
| 2021-01-03 | $7.30B 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |